Zuwu Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zuwu Wei has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Xiaolong Liu
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, P. R. China
3 shared publications Fuli Xin
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province
2 shared publications- Jingfeng Liu
Department of Hepatopancreatobiliary Surgery Fujian Cancer Hospital 350014 Fuzhou Fujian China
2 shared publications - Ming Wu
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou P. R. China
2 shared publications Bin Ning
College of Ecological Environment and Urban Construction, Fujian University of Technology, Fuzhou 350118, PR China
1 shared publicationBixing Zhao
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province
1 shared publication
Latest Publications
- 4 November 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (8) , 1302-1313
The combined effect of hypoxia activation and radiosensitization by a multifunctional nanoplatform system enhances the therapeutic efficacy of chemoradiotherapy in pancreatic cancer
- 4 November 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (8) , 1302-1313
The combined effect of hypoxia activation and radiosensitization by a multifunctional nanoplatform system enhances the therapeutic efficacy of chemoradiotherapy in pancreatic cancer
- 14 June 2021
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 9 (25) , 5083-5091
A remotely controlled NIR-II photothermal-sensitive transgene system for hepatocellular carcinoma synergistic therapy
Photothermal therapy (PTT) exhibits an excellent therapeutic effect in cancer treatment, but some cancers are still facing rapid recurrence due to the presence of heat-resistant cells, which express heat shock proteins (HSP) to defend against hyperthermia. Inspired by optogenetics, we firstly designed a caged TNF-related apoptosis-inducing ligand (TRAIL) expressing plasmid under HSP70 protomer (HSP70-TRAIL) as the thermal-activated gene therapy agent to induce the apoptosis of heat resistant cells. Then, the caged HSP70-TRAIL was decorated on the surface of the photothermal agent (semiconducting nanoparticles, SPNs) through electrostatic adsorption to obtain SPN@HSP70-TRAIL-GFP (SPNHT). Under 1064 nm near-infrared second region (NIR-II) laser irradiation, the SPNHT acted as an emerging photothermal agent for PTT. Importantly, the caged HSP70-TRAIL could be further activated by PTT to express TRAIL on demand to concurrently kill survival cells for overcoming the problem of tumor recurrence after PTT. Both in vitro and in vivo studies demonstrated that the SPNHT nano-system with the ability of NIR-II photothermal-triggered TRAIL in situ expression possessed an admirable synergistic anti-cancer efficacy for HCC. This work offers new tactics for effective treatment of cancer, which showed a great significance for reducing the rate of cancer recurrence after PTT treatment.
- 14 June 2021
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 9 (25) , 5083-5091
A remotely controlled NIR-II photothermal-sensitive transgene system for hepatocellular carcinoma synergistic therapy
Photothermal therapy (PTT) exhibits an excellent therapeutic effect in cancer treatment, but some cancers are still facing rapid recurrence due to the presence of heat-resistant cells, which express heat shock proteins (HSP) to defend against hyperthermia. Inspired by optogenetics, we firstly designed a caged TNF-related apoptosis-inducing ligand (TRAIL) expressing plasmid under HSP70 protomer (HSP70-TRAIL) as the thermal-activated gene therapy agent to induce the apoptosis of heat resistant cells. Then, the caged HSP70-TRAIL was decorated on the surface of the photothermal agent (semiconducting nanoparticles, SPNs) through electrostatic adsorption to obtain SPN@HSP70-TRAIL-GFP (SPNHT). Under 1064 nm near-infrared second region (NIR-II) laser irradiation, the SPNHT acted as an emerging photothermal agent for PTT. Importantly, the caged HSP70-TRAIL could be further activated by PTT to express TRAIL on demand to concurrently kill survival cells for overcoming the problem of tumor recurrence after PTT. Both in vitro and in vivo studies demonstrated that the SPNHT nano-system with the ability of NIR-II photothermal-triggered TRAIL in situ expression possessed an admirable synergistic anti-cancer efficacy for HCC. This work offers new tactics for effective treatment of cancer, which showed a great significance for reducing the rate of cancer recurrence after PTT treatment.
- 28 February 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 10 (10) , 2002036
Tumor Microenvironment Triggered Cascade‐Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common and deadliest malignancy cancers, which remains a major global health problem. At present, over 50% of patients with HCC have implemented systemic therapies, such as interventional therapy or local chemotherapy that are scarcely effective and induce serious side effects to the remaining normal liver, further limiting their clinical outcomes. Herein, a tumor microenvironment triggered cascade‐activation nanoplatform (A‐NPLap/TPZ) is prepared based on β‐lapachone (β‐Lap) and tirapazamine (TPZ) for the synergistic therapy of HCC. The A‐NPLap/TPZ exerts its targeting effect by binding to the receptor of tumor cells with an external aptamer. In the tumor microenvironment, the nanoplatform can realize H2O2‐triggered disassembly to release β‐Lap and TPZ. The released β‐Lap generates ROS to induce tumor cell apoptosis under the catalysis of the tumor cell over‐expressed NAD(P)H‐quinone oxidoreductase‐1 (NQO1) enzyme. In this process, oxygen is consumed to intensify tumor hypoxia, and eventually cascade activates TPZ to exert the anti‐tumor effect. The studies in vitro and in vivo consistently demonstrate that the as‐prepared A‐NPLap/TPZ nanoplatform possesses an excellent synergistic anti‐tumor effect. This design of nanoplatform with cascade activation effect provides a promising strategy for HCC treatment.
- 28 February 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 10 (10) , 2002036
Tumor Microenvironment Triggered Cascade‐Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common and deadliest malignancy cancers, which remains a major global health problem. At present, over 50% of patients with HCC have implemented systemic therapies, such as interventional therapy or local chemotherapy that are scarcely effective and induce serious side effects to the remaining normal liver, further limiting their clinical outcomes. Herein, a tumor microenvironment triggered cascade‐activation nanoplatform (A‐NPLap/TPZ) is prepared based on β‐lapachone (β‐Lap) and tirapazamine (TPZ) for the synergistic therapy of HCC. The A‐NPLap/TPZ exerts its targeting effect by binding to the receptor of tumor cells with an external aptamer. In the tumor microenvironment, the nanoplatform can realize H2O2‐triggered disassembly to release β‐Lap and TPZ. The released β‐Lap generates ROS to induce tumor cell apoptosis under the catalysis of the tumor cell over‐expressed NAD(P)H‐quinone oxidoreductase‐1 (NQO1) enzyme. In this process, oxygen is consumed to intensify tumor hypoxia, and eventually cascade activates TPZ to exert the anti‐tumor effect. The studies in vitro and in vivo consistently demonstrate that the as‐prepared A‐NPLap/TPZ nanoplatform possesses an excellent synergistic anti‐tumor effect. This design of nanoplatform with cascade activation effect provides a promising strategy for HCC treatment.
- 29 October 2018
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 6 (47) , 7889-7897
Facile preparation of biocompatible Ti 2 O 3 nanoparticles for second near-infrared window photothermal therapy
NIR-II photothermal therapy (PTT) agents of Ti 2 O 3 nanoparticles have been developed.
- 29 October 2018
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 6 (47) , 7889-7897
Facile preparation of biocompatible Ti 2 O 3 nanoparticles for second near-infrared window photothermal therapy
NIR-II photothermal therapy (PTT) agents of Ti 2 O 3 nanoparticles have been developed.